Since the last analysis, Novo Nordisk’s shares have climbed by approximately 30%, driven by renewed investor confidence in the company’s leadership in GLP-1 therapies. The rollout of its oral semaglutide formulation has solidified NVO’s first-mover status in the category, enabling the company to capture a disproportionate share of new patients transitioning from injectable treatments. Despite emerging competitors and potential pricing pressures in both obesity and diabetes markets, Novo Nordisk’s broad clinical data package—highlighting consistent reductions in HbA1c levels by up to 1.5 percentage points and weight losses exceeding 10% in obesity trials—underpins expectations for continued market share gains over the next five years.

IQVIA data for the first full week post-launch show 18,410 U.S. prescriptions for Novo Nordisk’s Wegovy® oral pill, underscoring strong demand for convenient obesity therapies. This initial prescription volume compares favorably to previous injectable launches, where first-week numbers were closer to 10,000 scripts, and suggests a faster adoption curve. Pharmacy fill rates exceeded 85%, indicating robust patient adherence and prescriber confidence. Analysts now model annual incremental revenue for the pill at over $1.2 billion by 2027, driven by expanded access programs and growing off-label use in metabolic disorders.

Goldman Sachs recently reaffirmed its “Buy” recommendation on Novo Nordisk and raised its forward target by roughly 24%, reflecting confidence in the company’s growth trajectory. The investment bank highlighted the strategic collaboration with Sesame to co-launch the Wegovy® pill as a key catalyst, projecting that the alliance will accelerate commercial rollout and enhance payer negotiations. Novo Nordisk’s market capitalization of around $277 billion positions it among the largest pure-play biopharmaceutical firms, and daily trading volumes remain elevated at over 9 million shares, signaling sustained investor interest in the story.